|
|
Main Topics:
- Epidemiology and risk stratification in healthy and sick population
- Genetics, arrhythmogenesis and cardiomiopathies
- Cellular and molecular mechanism of conduction disease and apoptosis
- New non-invasive markers for risk stratification
- New insights into the electrophysiological mechanism of AF initiation and perpetuation
- The ionic basis underlying the trigger of AF
- New drugs in development for the treatment of recurrent AF
- The comparative efficacy and safety of drug therapy vs catheter ablation for atrial flutter
- Limitations of current guidelines for anticoagulation in AF
- The prevalence and clinical significance of silent AF
- The interaction of AF and CHF and its clinical implications
- Drug-device interaction in the management of pacing, prevention and treatment of atrial tachyarrhythmias
- Echocardiography in the evaluation of the induced AF-mechanical remodelling
- Electrical or chemical implantable atrial defibrillator: always fancy or a new tool?
- New surgical strategies for AF
- Pulmonary Veins anatomy variability
- Ablation of AF in Pulmonary and Non-Pulmonary Foci
- Circumferential PV isolation: morbidity, mortality, QoL and long term outcomes
- The efficacy and safety of the cryosurgical maze procedure for refractory AF
- Role of drug therapy in the prevention of recurrence of AF
- Echo optimisation of atrial-ventricular delay in paced AF patients
- Atrial Fibrillation in children
- Latest indication to Cardiac Pacing
- New Pacing, Prevention and Cardioversion algorithms
- Telemedicine for the home follow-up of PM/ICD patients
- Latest pacing and ICD leads technology
- New generation of implantable cardiac haemodynamic sensors
- Advanced and expanded role of atrial and dual ICD
- New physiological ICD therapies
- Primary Prevention of Sudden Cardiac Death in different populations
- Percutaneous catheter ablation of ventricular arrhythmias
- Results of five years experiences of Cardiac AED Resuscitation programs
- Advances in the prevention of SCD with non-antiarrhythmic drugs
- Home defibrillation strategy in high risk patients
- Syncope: practical issues of diagnosis and treatment
- Physical treatment of neurally-mediated syncope
- Organizational models of Syncope Unit in 2005
- Modern management of chest pain and unexplained palpitations
- Neurohumoral activation in CHF patients
- Latest pharmacological therapy of CHF
- The HF doctor: still a role for clinicians?
- What results from new positive inotropic drugs in HF
- What lessons from the early terminated trials?
- Hybrid therapy in CHF and AF
- The optimal candidates to biventricular pacing
- Doppler echocardiography in the management of the resynchronisation in HF
- ICD backup in biventricular paced CHF patients: need of multiples therapy in a single device?
- Surgical transepicardic approach to CRT
- Management of hypertrophic and dilated cardiomiopathies
- New developments in cardiac imaging
- Role of surgery in end-stage CHF
- Data-banks in cardiology: an useful tool in the follow-up
- Expanding the target population for anti-platelet/coagulation therapy
- Global Cardiovascular Risk assessment and prevention
- Insulin Resistance Syndrome, type 2 Diabetes and Atherosclerosis: an explosive mixture
- Lipid-lowering therapy: do we need statins for all the life?
- Management of STEMI and non-STEMI patient
- Evolving therapies for Acute Myocardial Infarction: when PTCA, which stent?
- Hybrid myocardial revascularization therapy
- Fibrinolitics, IIb/IIIa inhibitors: till now beyond any expectation?
- Nuclear cardiology in CAD and CHF patients
- Spinal Cord Stimulation in refractory CAD: the last resort?
- Controversial issues: from clinical studies to real life
- Cost-effectiveness of drug/devices interaction
- Guidelines for AF, Arrhythmias, ACS, HF and Syncope
- Drug interaction, gender, age and comorbidities
- Elderly in cardiology: do we treat all patients in the same way?
- Late-breaking and ongoing clinical trials
- Sport and cardiac pathologies
|
|